Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer
U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas
Outcome of Annual General Meeting of May 19, 2020
Innate Pharma to present new efficacy data for monalizumab in combination with cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
Innate Pharma First Quarter 2020 Report
Number of shares and voting rights of Innate Pharma as at May 1, 2020
First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia
Innate Pharma files its 2019 Universal Registration Document (Document d'enregistrement universel) and its 2019 annual report on Form 20-F
Innate Pharma to hold its Annual General Meeting of shareholders on May 19, 2020 without the physical presence of its shareholders
Innate Pharma reports Full Year 2019 financial results and business update
